MGMandy Goldberg

Mandy Goldberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mandy Goldberg has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pubertal timing and incident uterine cancer in the Sister Study cohort

    by Ariayana N. Harrell, Katie M. O'BRien, Natalie D. Shaw, Dale P. Sandler, Mandy Goldberg

    Younger age at menarche is an established uterine cancer risk factor. Age at onset of breast development (thelarche), the earliest marker of pubertal “unopposed” estrogen exposure, may also be relevant to uterine cancer risk, particularly considering rapid declines in age at thelarche over time in parallel with increasing uterine cancer incidence rates. Using data from 34,152 participants with an intact uterus when they enrolled in the US Sister Study cohort (2003–2009; ages 35–74 years), we examined associations of self‐reported ages at thelarche and menarche with incident uterine cancer using multivariable‐adjusted Cox proportional hazards regression. We stratified by birth cohort, race, weight relative to peers in childhood, and body mass index (BMI) at enrollment to explore potential effect measure modification and tested for statistical heterogeneity across strata. During follow‐up (median = 13.3 years), 445 women reported an incident uterine cancer diagnosis. Ages at thelarche (hazard ratio [HR] per 1‐year older: 0.91, 95% confidence interval [CI]: 0.85–0.97) and menarche (HR per 1‐year older: 0.90, 95% CI: 0.84–0.96) were inversely associated with uterine cancer incidence. Associations were similar in non‐Hispanic Black and White women and did not vary by relative childhood weight or BMI in adulthood. Inverse associations of thelarche and menarche were limited to women born in 1950 or later ( p ‐het <.05). These findings suggest that younger ages at thelarche and menarche, markers of earlier and potentially prolonged exposure to estrogen in the absence of progesterone during puberty, may enhance susceptibility to uterine carcinogenesis.

  • Open Access

    Supplementary Table S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort

    by Sydney A. Lash, Katie M. O’bRien, Dale P. Sandler, Mandy Goldberg

    Supplementary Table S1 shows the hazard ratios and 95% confidence intervals for the associations of timing of thelarche and menarche jointly with incident ovarian cancer in the Sister Study cohort (n = 40,809 participants).

  • Open Access

    Data from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort

    by Sydney A. Lash, Katie M. O’bRien, Dale P. Sandler, Mandy Goldberg

    Background:Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence.Methods:With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype.Results:During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors.Conclusions:Ages at thelarche and menarche were not associated with ovarian cancer incidence overall.Impact:Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.

  • Open Access

    Supplementary Table S2 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort

    by Sydney A. Lash, Katie M. O’bRien, Dale P. Sandler, Mandy Goldberg

    Supplementary Table S2 shows the hazard ratios and 95% confidence intervals for the associations of age at thelarche and time from thelarche to menarche (pubertal tempo) with incident ovarian cancer among participants with age at thelarche at least one year before age at menarche (n = 18,679 participants).

  • Open Access

    Supplementary Figure S1 from Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort

    by Sydney A. Lash, Katie M. O’bRien, Dale P. Sandler, Mandy Goldberg

    Supplementary Figure S1 shows a flow chart of eligible Sister Study participants for this analysis.

  • Pubertal Timing and Incident Ovarian Cancer in the Sister Study Cohort

    by Sydney A. Lash, Katie M. O’bRien, Dale P. Sandler, Mandy Goldberg

    Background: Pubertal milestones such as menarche (first period) and thelarche (onset of breast development) are markers of hormonal changes that may be relevant to the hormonal etiology of ovarian cancer. Prior studies of the association between age at menarche and ovarian cancer risk have been inconsistent, whereas age at thelarche has not been examined in relation to ovarian cancer incidence. Methods: With data from 40,809 women in the Sister Study, we used multivariable-adjusted Cox proportional hazards regression to estimate HRs and 95% confidence intervals (CI) for associations of self-reported ages at thelarche and menarche with incident ovarian cancer, both overall and by histotype. Results: During a median follow-up of 13.3 years, 291 women reported a diagnosis of ovarian cancer. Ages at thelarche (HR = 0.94; 95% CI, 0.87–1.02 per 1-year older) and menarche (HR = 0.99; 95% CI, 0.91–1.07 per 1-year older) were not associated with ovarian cancer overall. Although imprecise, HRs suggested a possible inverse association of ages at thelarche (HR = 0.71; 95% CI, 0.48–1.04) and menarche (HR = 0.79; 95% CI, 0.59–1.04) with the incidence of clear-cell tumors. Conclusions: Ages at thelarche and menarche were not associated with ovarian cancer incidence overall. Impact: Though our results do not provide clear evidence of associations of pubertal timing with ovarian cancer incidence, possible associations of earlier thelarche and menarche with increased incidence of ovarian clear-cell carcinoma may warrant further investigation, especially considering secular trends toward earlier thelarche.

  • Environmental Phenols and Growth in Infancy: The Infant Feeding and Early Development Study

    by Danielle R Stevens, Mandy Goldberg, Margaret Adgent, Helen B Chin, Donna D Baird, Virginia A Stallings, Dale P Sandler, Antonia M Calafat, Eileen G Ford, Babette S Zemel, et al.

    Context: Higher mean and rapid increases in body mass index (BMI) during infancy are associated with subsequent obesity and may be influenced by exposure to endocrine-disrupting chemicals such as phenols. Objective: In a prospective US-based cohort conducted 2010-2014, we investigated associations between environmental phenol exposures and BMI in 199 infants. Methods: We measured 7 urinary phenols at ages 6-8 and 12 weeks and assessed BMI z-score at up to 12 study visits between birth and 36 weeks. We examined individual and joint associations of averaged early infancy phenols with level of BMI z-score using mean differences (β [95% CI]) and with BMI z-score trajectories using relative risk ratios (RR [95% CI]). Results: Benzophenone-3, methyl and propyl paraben, and all phenols jointly were positively associated with higher mean BMI z-score (0.07 [−0.05, 0.18], 0.10 [−0.08, 0.27], 0.08 [−0.09, 0.25], 0.17 [−0.08, 0.43], respectively). Relative to a stable trajectory, benzophenone-3, 2,4-dichlorophenol, 2,5-dichlorophenol, and all phenols jointly were positively associated with risk of a rapid increase trajectory (1.46 [0.89, 2.39], 1.33 [0.88, 2.01], 1.66 [1.03, 2.68], 1.41 [0.71, 2.84], respectively). Conclusion: Early phenol exposure was associated with a higher mean and rapid increase in BMI z-score across infancy, signaling potential long-term cardiometabolic consequences of exposure.


  • Environmental phenol exposures in 6- to 12-week-old infants: The Infant Feeding and Early Development (IFED) study

    by Mandy Goldberg, Margaret A. Adgent, Danielle R. Stevens, Helen B. Chin, Kelly K. Ferguson, Antonia M. Calafat, Gregory Travlos, Eileen G. Ford, Virginia A. Stallings, Walter J. Rogan, et al.


  • Personal Care Product Use during Puberty and Incident Breast Cancer among Black, Hispanic/Latina, and White Women in a Prospective US-Wide Cohort

    by Mandy Goldberg, Che-Jung Chang, Kemi Ogunsina, Katie M. O’BRien, Kyla W. Taylor, Alexandra J. White, Dale P. Sandler

    Some personal care products (PCPs) contain endocrine-disrupting chemicals that may affect breast cancer (BC) risk. Patterns of use vary by race and ethnicity. Use often starts in adolescence, when rapidly developing breast tissue may be more susceptible to environmental carcinogens. Few studies have examined associations of BC with PCP use during this susceptible window. We characterized race and ethnicity-specific patterns of PCP use at 10-13 years of age and estimated associations of use with incident BC. At enrollment (2003-2009), Sister Study participants (n=4,049 Black, 2,104 Latina, and 39,312 White women) 35-74 years of age reported use of 37 "everyday" PCPs during the ages of 10-13 y (did not use, sometimes, or frequently used). We conducted race and ethnicity-specific latent class analyses to separately identify groups of women with similar patterns of beauty, hair, and skincare/hygiene product use. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of identified PCP classes and single products with incident BC using Cox proportional hazards regression. During a mean follow-up time of 10.8 y, 280 Black, 128 Latina, and 3,137 White women were diagnosed with BC. Classes of adolescent PCP use were not clearly associated with BC diagnosis among Black, Latina, or White women. HRs were elevated but imprecise for frequent nail product and perfume use in Black women (HR=1.34; 95% CI: 0.85, 2.12) and greater hair product use in Black (HR=1.28; 95% CI: 0.91, 1.80) and Latina (HR=1.42; 95% CI: 0.81, 2.48) women compared with lighter use. In single-product models, we observed higher BC incidence associated with frequent use of lipstick, nail products, pomade, perfume, makeup remover, and acne/blemish products in at least one group. This work provides some support for the hypothesis that PCP use during puberty is associated with BC risk. More research is needed to confirm these novel findings. https://doi.org/10.1289/EHP13882.


  • Open Access

    Use of personal care product mixtures and incident hormone-sensitive cancers in the Sister Study: A U.S.-wide prospective cohort

    by Che-Jung Chang, Katie M. O'BRien, Alexander P. Keil, Mandy Goldberg, Kyla W. Taylor, Dale P. Sandler, Alexandra J. White